{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:30:14Z","timestamp":1758054614526,"version":"3.44.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Blue nevus is a benign melanocytic lesion that appears as a blue or dark mole due to the presence of melanin deep within the skin. In rare cases melanoma can arise from this association with blue nevus, and entity termed blue nevus melanoma (BNM). BNM most frequently occurs on the scalp and is an aggressive subtype of melanoma which has the tendency to metastasize. Similar to acral melanoma, BNM has a distinct genetic profile, is less linked to sun exposure, and has an equal incidence in patients of European and non-European ancestry. It is also less responsive to immunotherapy. This case report describes a diagnosis of blue nevus-related scalp melanoma characterized by GNA11 mutation in a 50-year-old female Hispanic patient, with a tumor refractory to multiple courses of combination immunotherapy who developed metastases to the liver and underwent microwave ablation of the hepatic lesions. Her disease course was complicated by hospitalization for infection with coronavirus disease of 2019 (COVID-19) and autoimmune hepatitis. Months after being discharged, surveillance imaging revealed a decrease in size of the existing lesions without additional therapeutic intervention. While this unusual response can be attributed to multiple factors, this observation aligns with emerging reports suggesting potential tumor remission associated with COVID-19 infection.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1658609","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:28:59Z","timestamp":1757914139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: An unexpected case of tumor regression in blue nevus melanoma following COVID-19 infection"],"prefix":"10.3389","volume":"16","author":[{"given":"Yadriel","family":"Bracero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya B.","family":"Kenchappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Berglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Fidvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyuan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Papalezova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne M.","family":"Saenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics\n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2394252","DOI":"10.1080\/21645515.2024.2394252","article-title":"Immunotherapy and delivery systems for melanoma","volume":"20","author":"Liu","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e438654","DOI":"10.1200\/EDBK_438654","article-title":"Curing stage IV melanoma: where have we been and where are we","volume":"44","author":"Chan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.62","article-title":"Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature","volume":"27","author":"Loghavi","year":"2014","journal-title":"Mod Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009609","article-title":"Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma","volume":"12","author":"Kudelka","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjh.17116","article-title":"SARS-CoV-2-induced remission of Hodgkin lymphoma","volume":"192","author":"Challenor","year":"2021","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2022.01.017","article-title":"COVID-19 induced follicular lymphoma remission","volume":"44","author":"Baptista","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i3.10141","article-title":"Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma","volume":"91","author":"Pasin","year":"2020","journal-title":"Acta BioMed"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1992117","article-title":"Could COVID-19 induce remission of acute leukemia","volume":"26","author":"Kandeel","year":"2021","journal-title":"Hematology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7181\/acfs.2023.00024","article-title":"Malignant melanoma associated with a plaque-type blue nevus of the cheek: a case report","volume":"24","author":"Chung","year":"2023","journal-title":"Arch Craniofac Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e13804","DOI":"10.1097\/MD.0000000000013804","article-title":"Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report","volume":"98","author":"Lepir","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1290696","article-title":"An update on methods for detection of prognostic and predictive biomarkers in melanoma","volume":"11","author":"Adeuyan","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17588359211011455","DOI":"10.1177\/17588359211011455","article-title":"Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection","volume":"13","author":"Ottaiano","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2336","DOI":"10.1097\/MD.0000000000002336","article-title":"GNA11 mutation in a patient with cutaneous origin melanoma: A case report","volume":"95","author":"Patel","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v16.i7.1969","article-title":"Impact of immunotherapy on liver metastasis","volume":"16","author":"Fu","year":"2024","journal-title":"World J Gastrointest Surg"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:29:01Z","timestamp":1757914141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2025.1658609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1658609"}}